心肌梗死患者FFR指导的完全血运重建与仅罪犯病变PCI比较
这项多国、基于注册的随机试验纳入STEMI或极高危NSTEMI合并多支病变、正接受罪犯病变直接PCI的患者,随机分配至FFR指导的非罪犯病变完全血运重建组(764例)或仅罪犯病变PCI组(778例)。主要终点为全因死亡、心肌梗死或非计划血运重建的复合终点,中位随访4.8年(四分位距4.3-5.2)。结果显示主要终点事件在完全血运重建组145例(19.0%)与仅罪犯病变组159例(20.4%)之间无显著差异(HR 0.93;95%CI 0.74-1.17;P=0.53)。关键次要终点全因死亡或心肌梗死(HR 1.12;95%CI 0.87-1.44)和非计划血运重建(HR 0.76;95%CI 0.56-1.04)亦无显著组间差异,安全性结局无显著差异。
要点
- 在中位随访4.8年时,FFR指导完全血运重建组主要终点事件19.0%(145例)vs 仅罪犯病变组20.4%(159例),HR 0.93(95%CI 0.74-1.17;P=0.53),未达统计学显著。
- 全因死亡或心肌梗死复合终点:HR 1.12(95%CI 0.87-1.44),两组无显著差异。
- 非计划血运重建:HR 0.76(95%CI 0.56-1.04),两组无显著差异。
- 安全性结局两组无显著差异。
- 研究纳入STEMI或极高危NSTEMI合并多支病变、正接受罪犯病变直接PCI的患者。
适用人群与场景
- STEMI或极高危NSTEMI合并多支冠状动脉病变、正接受罪犯病变直接PCI的患者。
处置流程与药物剂量
- 随机分配至FFR指导的非罪犯病变完全血运重建或仅罪犯病变PCI(不再进一步血运重建)。
研究设计与关键结果
- 多国、基于注册的随机试验,共随机1542例患者,完全血运重建组764例,仅罪犯病变PCI组778例。
- 中位随访4.8年(四分位距4.3-5.2),主要终点(全因死亡、心肌梗死或非计划血运重建复合终点)事件:完全血运重建组145例(19.0%)vs 仅罪犯病变组159例(20.4%),HR 0.93(95%CI 0.74-1.17;P=0.53)。
- 关键次要终点全因死亡或心肌梗死:HR 1.12(95%CI 0.87-1.44),两组无显著差异。
- 关键次要终点非计划血运重建:HR 0.76(95%CI 0.56-1.04),两组无显著差异。
- 安全性结局两组无显著差异。
证据类型、等级与局限
- 证据类型:多国、基于注册的随机试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在STEMI或极高危NSTEMI合并多支病变、正接受罪犯病变直接PCI的患者中,FFR指导的完全血运重建在4.8年时未显示较仅罪犯病变PCI降低全因死亡、心肌梗死或非计划血运重建复合终点风险。
指南或共识出处
- FULL REVASC试验(ClinicalTrials.gov注册号NCT02862119),由瑞典研究理事会等资助。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The benefit of fractional flow reserve (FFR)-guided complete revascularization in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel coronary artery disease remains unclear.
METHODS: In this multinational, registry-based, randomized trial, we assigned patients with STEMI or very-high-risk non-STEMI (NSTEMI) and multivessel disease who were undergoing primary percutaneous coronary intervention (PCI) of the culprit lesion to receive either FFR-guided complete revascularization of nonculprit lesions or no further revascularization. The primary outcome was a composite of death from any cause, myocardial infarction, or unplanned revascularization. The two key secondary outcomes were a composite of death from any cause or myocardial infarction and unplanned revascularization.
RESULTS: A total of 1542 patients underwent randomization, with 764 assigned to receive FFR-guided complete revascularization and 778 assigned to receive culprit-lesion-only PCI. At a median follow-up of 4.8 years (interquartile range, 4.3 to 5.2), a primary-outcome event had occurred in 145 patients (19.0%) in the complete-revascularization group and in 159 patients (20.4%) in the culprit-lesion-only group (hazard ratio, 0.93; 95% confidence interval [CI], 0.74 to 1.17; P = 0.53). With respect to the secondary outcomes, no apparent between-group differences were observed in the composite of death from any cause or myocardial infarction (hazard ratio, 1.12; 95% CI, 0.87 to 1.44) or unplanned revascularization (hazard ratio, 0.76; 95% CI, 0.56 to 1.04). There were no apparent between-group differences in safety outcomes.
CONCLUSIONS: Among patients with STEMI or very-high-risk NSTEMI and multivessel coronary artery disease, FFR-guided complete revascularization was not shown to result in a lower risk of a composite of death from any cause, myocardial infarction, or unplanned revascularization than culprit-lesion-only PCI at 4.8 years. (Funded by the Swedish Research Council and others; FULL REVASC ClinicalTrials.gov number, NCT02862119.).
参考来源
- Böhm F, Mogensen B, Engstrøm T, et al. FFR-Guided Complete or Culprit-Only PCI in Patients with Myocardial Infarction. N Engl J Med. 2024. PMID: 38587995. doi:10.1056/NEJMoa2314149
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。